PAHC Earnings

PAHC reported its FY2026Q2 earnings on 2026-02-05, showcasing a revenue of 0.00 against an estimate of 357.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.69 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following PAHC's FY2026Q2 earnings announcement on 2026-02-05, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, PAHC's stock price tends to shift by an average of -7.62% in the 10 days leading up to earnings and +6.12% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate PAHC’s annual revenue to reach 356.00M, while the EPS is projected at 1.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.37% and EPS estimates Revise Downward by -0.92% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between PAHC's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2026 were Revise Upward by 0.37%, while EPS estimates moved Revise Downward by -0.92% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PAHC's stock price typically moves by -7.62% in the 10 days before its earnings and +6.12% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 1.00 and revenue of 356.00M.

The earnings call reveals strong financial performance, with notable growth in net sales and adjusted EBITDA, especially in the Animal Health segment. The optimistic guidance and strategic initiatives, such as the Phibro Forward Initiative and Zoetis portfolio contributions, support a positive outlook. Despite some uncertainties in growth sustainability, management's confidence in demand and profitability, along with strategic expansions into companion animals, suggest a favorable market reaction. The decision not to update guidance reflects caution rather than negative sentiment, aligning with a positive stock price outlook.